Terms: = Prostate cancer AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Clinical Outcome
17 results:
1. Tumor-Induced Osteomalacia in Patients With Malignancy: A meta-analysis and Systematic Review of Case Reports.
Bouraima F; Sapin V; Kahouadji S; Pickering ME; Pereira B; Bouvier D; Oris C
J Clin Endocrinol Metab; 2023 Oct; 108(11):3031-3040. PubMed ID: 37235783
[TBL] [Abstract] [Full Text] [Related]
2. MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer.
Fenor MD; Ruiz-Llorente S; Rodríguez-Moreno JF; Caleiras E; Torrego JC; Sevillano-Fernández E; Navarro P; Yagüe-Fernández M; Amarilla-Quintana S; Barquín A; García-Donas J
Clin Transl Oncol; 2022 Dec; 24(12):2432-2440. PubMed ID: 35994225
[TBL] [Abstract] [Full Text] [Related]
3. aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in
Nickols N; Anand A; Johnsson K; Brynolfsson J; Borreli P; Parikh N; Juarez J; Jafari L; Eiber M; Rettig M
J Nucl Med; 2022 Feb; 63(2):233-239. PubMed ID: 34049980
[TBL] [Abstract] [Full Text] [Related]
4. A copy number gain on 18q present in primary prostate tumors is associated with metastatic outcome.
Ashcraft KA; Johnson-Pais TL; Troyer DA; Hernandez J; Leach RJ
Urol Oncol; 2020 Dec; 38(12):932.e1-932.e7. PubMed ID: 32665124
[TBL] [Abstract] [Full Text] [Related]
5. Radioablation +/- hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159).
Marvaso G; Ciardo D; Corrao G; Gandini S; Fodor C; Zerini D; Rojas DP; Augugliaro M; Bonizzi G; Pece S; Cattani F; Mazzocco K; Mistretta FA; Musi G; Alessi S; Petralia G; Pravettoni G; De Cobelli O; Di Fiore PP; Viale G; Orecchia R; Jereczek-Fossa BA
BMC Cancer; 2019 Sep; 19(1):903. PubMed ID: 31500605
[TBL] [Abstract] [Full Text] [Related]
6. Retrospective evaluation of nitrofurantoin and pivmecillinam for the treatment of lower urinary tract infections in men.
Montelin H; Forsman KJ; Tängdén T
PLoS One; 2019; 14(1):e0211098. PubMed ID: 30682092
[TBL] [Abstract] [Full Text] [Related]
7. Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer.
Johnston WL; Catton CN; Swallow CJ
BMC Urol; 2019 Jan; 19(1):4. PubMed ID: 30616540
[TBL] [Abstract] [Full Text] [Related]
8. methylation status of insulin-like growth factor-binding protein 7 concurs with the malignance of oral tongue cancer.
Chen LH; Liu DW; Chang JL; Chen PR; Hsu LP; Lin HY; Chou YF; Lee CF; Yang MC; Wen YH; Hsu WL; Weng CF
J Exp Clin Cancer Res; 2015 Feb; 34(1):20. PubMed ID: 25880247
[TBL] [Abstract] [Full Text] [Related]
9. MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer.
Adler D; Menon R; Braun M; Offermann A; Queisser A; Boehm D; Vogel W; Rüenauver K; Ruiz C; Zellweger T; Svensson M; Andren O; Kristiansen G; Wernert N; Bubendorf L; Kirfel J; Biskup S; Perner S
Int J Cancer; 2014 Jul; 135(1):19-26. PubMed ID: 24374838
[TBL] [Abstract] [Full Text] [Related]
10. Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer.
Servoll E; Saeter T; Vlatkovic L; Lund T; Nesland J; Waaler G; Axcrona K; Beisland HO
BJU Int; 2012 May; 109(10):1489-94. PubMed ID: 21933333
[TBL] [Abstract] [Full Text] [Related]
11. Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis.
Yu YP; Yu G; Tseng G; Cieply K; Nelson J; Defrances M; Zarnegar R; Michalopoulos G; Luo JH
Cancer Res; 2007 Sep; 67(17):8043-50. PubMed ID: 17804715
[TBL] [Abstract] [Full Text] [Related]
12. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract] [Full Text] [Related]
13. Biomarker discovery in urogenital cancer.
Said J
Biomarkers; 2005 Nov; 10 Suppl 1():S83-6. PubMed ID: 16298916
[TBL] [Abstract] [Full Text] [Related]
14. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?
Kuban D; Thames H; Levy L; Horwitz E; Kupelian P; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):409-14. PubMed ID: 15667960
[TBL] [Abstract] [Full Text] [Related]
15. Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma.
Strohmeyer D; Strauss F; Rössing C; Roberts C; Kaufmann O; Bartsch G; Effert P
Anticancer Res; 2004; 24(3a):1797-804. PubMed ID: 15274358
[TBL] [Abstract] [Full Text] [Related]
16. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.
Thames H; Kuban D; Levy L; Horwitz EM; Kupelian P; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):929-43. PubMed ID: 14575823
[TBL] [Abstract] [Full Text] [Related]
17. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
[TBL] [Abstract] [Full Text] [Related]
